SAGE THERAPEUTICS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
SAGE THERAPEUTICS INC. - More news...
SAGE THERAPEUTICS INC. - More news...
- SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
- Thinking about trading options or stock in Tesla, Fluor, SAGE Therapeutics, D-Wave Quantum, or Tupperware Brands?
- Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
- FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
- Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
- Sage Therapeutics to Present at Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
- Sage Therapeutics to Present at the Stifel 2023 CNS Days
- Sage Therapeutics Appoints Jessica Federer to Board of Directors
- Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
- Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
- Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
- Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
- Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
- Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
- Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
- Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
- Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
- Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
- Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
- Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
- Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
- Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
- Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
- Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
